4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine | 299180-15-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine
• 英文别名: 4,5,6,7-tetrahydro-1H-indazol-5-ylmethanamine
• CAS: 299180-15-7
• 化学式: C₈H₁₃N₃
• 分子量: 151.211
• InChiKey: WHACGQRDMGNJBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [3-[(苄基磺酰基)氨基]-6-甲基-2-氧代-1,2-二氢吡啶基]乙酸 、 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine 在 N-甲基吗啉 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 2-(6-Methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-N-(4,5,6,7-tetrahydro-2H-indazol-5-ylmethyl)-acetamide
  参考文献：
  名称：

  Selective 3-Amino-2-pyridinone acetamide thrombin inhibitors incorporating weakly basic partially saturated heterobicyclic P1-Arginine mimetics

  摘要：

  Novel, highly selective and potent thrombin inhibitors were identified as a result of combing the 3-benzylsulfonylamino-2-pyridinone acetamide P-2-P-3 surrogate with weakly basic partially saturated heterobicyclic P-1-arginine mimetics 1-8. The design, synthesis. biological activity, and the binding modes of non-covalent thrombin inhibitors featuring P-1-4,5,6,7-tetrahydroindazole, 5,6,7,8-tetrahydroquinazoline, and 4,5,6,7-tetrahydrobenzothiazole moieties are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00717-0
• 作为产物：
  描述：

  4-氰基环己酮缩乙二醇 在 盐酸 、 lithium aluminium tetrahydride 、 甲酸 、 一水合肼 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 57.0h， 生成 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine
  参考文献：
  名称：

  A general synthesis of novel conformationally restricted arginine side-chain mimetics

  摘要：

  6-(Aminomethyl)-5,6,7,8-tetrahydro-2-quinazolinamine and 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine were synthesized as novel conformationally restricted arginine side-chain mimetics, designed for incorporation into trypsin-like serine protease inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)00869-8

文献信息

• Anticoagulant contrast media
  申请人：Melton J. Laura

  公开号：US20050281746A1

  公开（公告）日：2005-12-22

  The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

  本发明提供了一种新型抗凝对比剂，包括有机支架基团、有机抗凝基团和成像基团。该发明还提供了抗凝对比介质和利用新型抗凝对比剂和抗凝对比介质来可视化内部结构的方法。
• Thrombin inhibitors
  申请人：——

  公开号：US20030191139A1

  公开（公告）日：2003-10-09

  The invention relates to compounds of formula I D—CO—B—A-Het and pharmaceutically acceptable salts thereof where substituents in description have the specified meanings. The compounds are used as thrombin inhibitors.

  该发明涉及公式I的化合物D—CO—B—A-Het及其药用可接受的盐，其中描述中的取代基具有指定的含义。这些化合物被用作凝血酶抑制剂。
• Novel pyrazinone and pyridinone thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics
  作者：Andreja Kranjc、Lucija Peterlin Mašič、Sebastjan Reven、Klemen Mikic、Andrej Preželj、Mojca Stegnar、Danijel Kikelj

  DOI：10.1016/j.ejmech.2005.03.007

  日期：2005.8

  The design, synthesis and biological activity of new thrombin inhibitors with a pyridinone or pyrazinone core and different heterobicyclic P(1) arginine side-chain mimetics are described. The arginine side-chain mimetics used in this study are (+/-)-4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine and both enantiomers thereof, (+/-)-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine and the corresponding

  设计，合成和生物活性的新型凝血酶抑制剂具有吡啶酮或吡嗪酮核心和不同的杂环双（P）（1）精氨酸侧链模拟物。在这项研究中使用的精氨酸侧链模拟物是（+/-）-4,5,6,7-四氢-2H-吲唑-5-基甲胺及其两种对映体（+/-）-4,5,6 ，7-四氢-1，3-苯并噻唑-2，6-二胺和相应的R对映体。吡嗪酮系列抑制剂中最有效的化合物25在体外的K（i）为41 nM，对胰蛋白酶和Xa因子的选择性高。
• [EN] ΡΡΑRγ MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS DE ΡΡΑRγ ET MÉTHODES D'UTILISATION
  申请人：EISAI R&D MANGEMENT CO LTD

  公开号：WO2022099144A1

  公开（公告）日：2022-05-12

  Disclosed herein are novel PPARy modulators of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same, in particular for the treatment of cancers.

  本文公开了一种新型的PPARy调节剂，其化学式为（I），以及其药学上可接受的盐，包含它们的制药组合物，以及使用它们的方法，特别是用于治疗癌症的方法。
• Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties
  作者：Andreja Kranjc、Lucija Peterlin-Mašič、Janez Ilaš、Andrej Preželj、Mojca Stegnar、Danijel Kikelj

  DOI：10.1016/j.bmcl.2004.03.085

  日期：2004.6

  Optimization of lead compounds I and 2 resulted in novel, selective, and potent thrombin inhibitors incorporating weakly basic heterobicyclic P-1-arginine mimetics. The design, synthesis, and biological activity of racemic thrombin inhibitors 17-29 and enantiomerically pure thrombin inhibitors 30-33 are described. The arginine side-chain mimetics used in this study are 4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine, 4,5,6,7-tetrahydro-2H-indazole, and 2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl-amine. (C) 2004 Elsevier Ltd. All rights reserved.